

H g K g E cha ge, a d C ea g L ed a d The S c E cha ge f H g K g L ed, a e e, , b f he
c e f h, a ce e, a e e e, e a, a, acc ac c e e e, a d e e, , d, c a a
ab ha e e f a , h , e e a , g f e a ce he h e a a f, he c e f h,
a ce e

FOSUN PHARMA 复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a f c ed c a c a ed he Pe e, Re b c f Ch a h ed ab)
(Stock Code: 02196)

2019 THIRD QUARTERLY REPORT

T t R 13.09(2) R 13.10B t R G t
L t S t T S E t H t K t L t I I t
P t P t I A t S t F t O (C . 571 t L / H t
K t).

T / t t t 2019 S t F t P t (G) C .,
I . * t “Company”, t t t , t t “Group”) t “2019 Third
Quarterly Report”). T t PRC A t t
S B E t t t .

B t B
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Cha a

S t P t R t
29 O t 2019

A, a he da e f h, a ce e he e ec ed ec, f he C a a e M . Che Q , M . Ya Fa g a d M . W
Yfa g; he -e ec ed ec, f he C a a e M . X Xa a g, M . Wa g Ca , M . M Ha g a d M . La g
Ja fe g; a d he de e de -e ec ed ec, f he C a a e M . Ja g Xa , D . W g T Ya Ke , M .
L L g a d M . Ta g G a g.

* f de f ca , e,

1. IMPORTANT NOTICE

- 1.1 The “Board”) “Supervisory Committee”) C 2019 Q R G
- 1.2 A C B 2019 Q R G
- 1.3 C Q C , G C F O , C D A D (A O) 2019 Q R G
- 1.4 2019 Q R G

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

2.1 Major financial information

Unit: CNY; Currency: RMB

	30 September 2019	31 December 2018	Ratio of change (%)
Total assets	78,569,297,725.65	70,551,361,387.48	11.36
Net assets attributable to equity holders of the parent	30,633,746,877.27	27,977,736,427.49	9.49
	Jan - Sept 2019	Jan - Sept 2018	Period-on-period change (%)
Net assets attributable to equity holders of the parent	2,328,355,784.17	2,087,826,458.74	11.52
	Jan - Sept 2019	Jan - Sept 2018	Period-on-period change (%)
Operating revenue	21,227,618,679.11	18,142,384,871.95	17.01
Net profit attributable to equity holders of the parent	2,063,704,147.99	2,094,152,353.81	-1.45
Net profit attributable to equity holders of the parent	1,722,388,028.34	1,591,668,096.39	8.21
Profit margin (%)	7.21	8.00	Decrease 0.79
Basic earnings per share (RMB/)	0.81	0.83	-2.41
Diluted earnings per share (RMB/)	0.81	0.83	-2.41

Note: In 2019, the Group's operating revenue (including tax) increased by RMB163.7726 billion, or 41.88%, compared with RMB116.5146 billion in 2018. The increase is mainly due to the increase in operating revenue of the Group's main business, which increased by RMB554.7841 billion, or 41.88%, compared with RMB116.5146 billion in 2018. The increase is mainly due to the increase in operating revenue of the Group's main business, which increased by RMB554.7841 billion, or 41.88%, compared with RMB116.5146 billion in 2018.

The Group's net profit attributable to equity holders of the parent decreased by RMB130.7199 billion, or 1.45%, compared with RMB1,722.388 billion in 2018. The decrease is mainly due to the increase in operating expenses, which increased by RMB149.8699 billion, or 32.07%, compared with RMB341.3161 billion in 2018. The increase is mainly due to the increase in operating expenses of the Group's main business, which increased by RMB161.1681 billion, or 32.07%, compared with RMB341.3161 billion in 2018.

The Group's basic earnings per share decreased by RMB30.4482, or 1.45%, compared with RMB341.3161 in 2018. The decrease is mainly due to the increase in operating expenses, which increased by RMB149.8699 billion, or 32.07%, compared with RMB341.3161 billion in 2018. The increase is mainly due to the increase in operating expenses of the Group's main business, which increased by RMB161.1681 billion, or 32.07%, compared with RMB341.3161 billion in 2018.

The Group's diluted earnings per share decreased by RMB2,253.454, or 20.70%, compared with RMB386.4802 in 2018. The decrease is mainly due to the increase in operating expenses, which increased by RMB149.8699 billion, or 32.07%, compared with RMB341.3161 billion in 2018. The increase is mainly due to the increase in operating expenses of the Group's main business, which increased by RMB161.1681 billion, or 32.07%, compared with RMB341.3161 billion in 2018.

Et

Unit: C : RMB

Items	Jul – Sept 2019	Jan – Sept 2019
G	6,698,974.15	54,877,229.54
G	64,610,828.53	123,804,343.06
P	-95,402,673.43	231,996,093.58
N	48,756,541.22	27,391,712.25
I	-15,445,568.08	-33,058,160.48
E	-16,417,943.49	-63,695,098.30
T	-7,199,841.10	341,316,119.65

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
SHANGHAI FOSUN HIGH TECHNOLOG (GROUP) COMPAN LIMITED*	938,095,290	RMB	938,095,290
HKSCC NOMINEES LIMITED (N _o 1)	551,255,448	O.	551,255,448
CHINA SECURITIES FINANCE CORPORATION LIMITED*	38,736,157	RMB	38,736,157
HONG KONG SECURITIES CLEARING COMPAN LIMITED (N _o 2)	36,199,707	RMB	36,199,707
NATIONAL SOCIAL SECURIT FUND 113 PORTFOLIO*	28,066,210	RMB	28,066,210
BASIC PENSION INSURANCE FUND 802 PORTFOLIO*	25,824,892	RMB	25,824,892
CENTRAL HUIJIN ASSET MANAGEMENT LTD.*	24,067,700	RMB	24,067,700
NATIONAL SOCIAL SECURIT FUND 110 PORTFOLIO*	15,358,518	RMB	15,358,518
ABU DHABI IN ESTMENT AUTHORIT	13,790,532	RMB	13,790,532
CHINA CONSTRUCTION BANK CORPORATION – CHINA-EUROPE ALUE DISCO ER EQUIT SECURITIES IN ESTMENT FUND*	10,198,273	RMB	10,198,273

N_o 1: HKSCC NOMINEES LIMITED, . . . H K S C C N L , R P 34,993,500
H C S F H T (G) C , L * (“Fosun High Tech”) . . . 1.37% . . . C . . . R . . . P . . .

N_o 2: HONG KONG SECURITIES CLEARING COMPAN LIMITED . . . RMB . . . S -H K S C . . .

2.3 T . . . T 10 . . . C . . . R . . . P . . . N . . .

(3) Statement of Cash Flow

Unit: CNY; RMB

Statement of Cash Flow				
Items	Jan – Sept 2019	Jan – Sept 2018	Ratio of change	Reasons of changes
Net cash flow from operating activities	-2,560,243,375.55	-4,338,289,449.60	40.98%	Mainly due to the impact of the SHL and CMF on the RMB and P
End of period cash and cash equivalents	47,762,255.60	-31,014,791.25	254.00%	Mainly due to the RMB and P

3.2 Analysis of the change in cash and cash equivalents

1. In 2016, the company's cash and cash equivalents increased by RMB10 million compared to the end of 2015. This was mainly due to the impact of the RMB10 million MTN (N. 208) and the 2018 SCP (N. 90) on the RMB and P. In addition, the company's cash and cash equivalents also increased by RMB5 million due to the impact of the 2018 SCP (N. 90) on the RMB and P.

The company's cash and cash equivalents also increased by RMB300 million due to the impact of the 2019 SCP (N. 90) on the RMB and P. The company's cash and cash equivalents also increased by RMB300 million due to the impact of the 2019 SCP (N. 90) on the RMB and P.

2. On 19 September 2019, the company's cash and cash equivalents increased by RMB100 million due to the impact of the 2019 SCP (N. 90) on the RMB and P. The company's cash and cash equivalents also increased by RMB100 million due to the impact of the 2019 SCP (N. 90) on the RMB and P. The company's cash and cash equivalents also increased by RMB100 million due to the impact of the 2019 SCP (N. 90) on the RMB and P.

At the Report, F H T 2,560,000 H
 C RMB53.54
 0.10% C 19 S 2019.

3. On 27 November 2018, 2018 C
 (“Shanghai Henlius”),
 (H) M B T S
 E H K L (“Hong Kong Stock Exchange”).

On 25 September 2019, H K S E H
 S H M B H K S
 E S H 64,695,400 H
 HK\$49.60 G O ()
 HK\$3,208.89 . A 30 S 2019,
 S H C)
 53.76%.

On 17 October 2019, S H
 4,366,400 H HK\$49.60
 HK\$210.49 . U
 S H C)
 53.33%.

3.3 F R P

N

3.4

N

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

L R : Chen Qiyu

29 October 2019

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: CNY; RMB Thousand

Items	30 September 2019	31 December 2018
Current assets:		
Monetary assets	10,307,237,302.85	8,546,521,777.04
Financial assets	1,344,673,568.10	616,123,764.39
Receivables	258,620,513.78	712,510,581.95
Prepaid expenses	4,463,034,533.86	3,623,640,740.82
Other receivables	471,597,865.70	—
Inventory	596,927,301.93	472,144,580.30
Other current assets	577,591,869.92	447,434,579.55
Intangible assets	9,995,755.01	11,660,016.68
Deferred tax assets	36,917,475.21	19,731,451.25
Other non-current assets	3,858,842,830.18	3,287,392,199.46
Non-current financial assets	—	—
Other non-current assets	1,162,820,637.56	—
Other non-current assets	368,970,686.90	295,958,970.62
Other non-current assets	23,410,317,110.78	18,001,727,194.13
Non-current assets:		
Property, plant and equipment	117,956,750.00	67,562,000.00
Intangible assets	21,198,447,942.66	21,427,527,810.80
Other non-current assets	100,986,503.54	126,313,106.69
Other non-current assets	2,100,733,208.89	2,505,806,955.75
Financial assets	7,291,387,236.53	7,083,251,505.14
Other non-current assets	2,942,095,697.03	2,039,800,319.91
Other non-current assets	433,996,758.51	—
Intangible assets	7,873,710,459.21	7,151,343,109.87
Other non-current assets	2,676,735,574.42	2,040,773,501.88
Other non-current assets	9,187,137,617.57	8,853,913,413.52
Other non-current assets	114,180,385.70	95,198,631.30
Other non-current assets	242,021,035.79	173,134,814.17
Other non-current assets	879,591,445.02	985,009,024.32
Other non-current assets	55,158,980,614.87	52,549,634,193.35
Other non-current assets	78,569,297,725.65	70,551,361,387.48

Consolidated balance sheet (Continued)

30 September 2019

Items	30 September 2019	31 December 2018
Current liabilities:		
Accounts payable	7,440,018,220.78	5,607,192,955.63
Bank deposits	266,942,486.20	149,003,072.96
Trade receivables	2,233,670,981.77	2,184,280,272.14
Prepaid expenses	562,709,265.76	578,701,499.77
Trade payables	451,969,450.66	478,905,270.26
Other payables	4,178,903,272.34	3,237,217,890.12
Interest payable	220,768,148.00	187,344,429.18
Dividends payable	139,956,011.68	125,420,505.60
Contract liabilities	388,047,456.85	530,896,724.79
Non-current liabilities	2,206,056,772.37	4,929,603,365.34
Other liabilities	1,599,149,293.47	227,445,337.32
Total current liabilities	19,327,467,200.20	17,923,246,388.33
Non-current liabilities:		
Long-term debt	8,816,140,333.28	8,630,661,547.43
Bank deposits	5,781,204,728.90	4,039,456,986.21
Long-term debt	307,212,833.42	—
Long-term debt	252,679,111.96	416,889,805.19
Dividends payable	358,341,043.66	363,489,177.57
Deferred income	2,895,818,060.31	2,908,359,008.27
Other non-current liabilities	2,878,227,018.69	2,676,545,098.82
Total non-current liabilities	21,289,623,130.22	19,035,401,623.49
Total liabilities	40,617,090,330.42	36,958,648,011.82
Equity:		
Parent's equity (attributable to parent)	2,562,898,545.00	2,563,060,895.00
Minority interest	11,918,086,638.94	10,544,648,359.54
Long-term equity investments	—	1,711,169.00
Other equity	-238,833,703.62	-274,779,732.99
Surplus	2,373,685,050.45	2,374,999,312.51
Unrealized gains	14,017,910,346.50	12,771,518,762.43
Total equity (attributable to parent and minority interest)	30,633,746,877.27	27,977,736,427.49
Non-current liabilities	7,318,460,517.96	5,614,976,948.17
Total equity (attributable to parent)	37,952,207,395.23	33,592,713,375.66
Total liabilities and equity (attributable to parent)	78,569,297,725.65	70,551,361,387.48

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Deputy Chief Accounting Officer:
Chen Zhanyu

Balance Sheet of the Parent Company

30 September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: CNY; RMB Tenthousand; U.S. Dollar

Items	30 September 2019	31 December 2018
Current assets:		
Cash	1,106,498,344.52	850,102,168.54
Financial assets		
Prepaid expenses		
Receivables	6,407,634,690.21	6,914,735,852.92
Inventory	299,410,098.84	230,691,574.83
Due from related parties	354,609,680.05	307,409,680.05
Intangible assets	—	—
Non-current receivables	2,536,000,000.00	1,625,000,000.00
Other current assets	239,000,000.00	158,570,000.00
Total	10,289,133,034.73	9,548,408,021.46
Non-current assets:		
Due to related parties	6,011,804,080.60	5,465,151,645.71
Long-term receivables	23,961,991,164.92	22,999,277,541.00
Other non-current assets	37,689,534.30	37,626,487.24
Other non-current receivables	147,179,403.98	184,188,803.45
Fixed assets	6,217,807.54	7,158,298.77
Current liabilities	2,305,418.41	2,305,418.41
Intangible liabilities	1,398,139.68	1,840,272.04
Due to related parties		
Guarantees		
Long-term liabilities		
Deferred tax liabilities		
Total	30,168,585,549.43	28,697,548,466.62
Total	40,457,718,584.16	38,245,956,488.08

Balance Sheet of the Parent Company (Continued)

30 September 2019

Items	30 September 2019	31 December 2018
Current liabilities:		
Accounts payable	3,825,000,000.00	2,959,000,000.00
Bank borrowings		
Reservable		
Contract liabilities		
Prepaid expenses	94,480,035.63	124,637,901.93
Trade receivables	25,239,506.72	43,694,651.68
Other receivables	1,715,449,403.09	1,357,247,173.94
Interest payable	213,542,735.45	172,658,261.16
Dividends payable	229,468.00	229,468.00
Non-current liabilities	1,267,088,795.71	3,769,010,861.94
Other non-current liabilities	1,304,675,980.01	5,313,103.87
Total current liabilities	8,231,933,721.16	8,258,903,693.36
Non-current liabilities:		
Long-term debt	346,740,000.00	66,740,000.00
Bank borrowings	5,781,204,728.90	4,039,456,986.21
Long-term debt		
Derivatives	325,000.00	550,000.00
Derivatives	1,151,018,873.79	1,151,018,873.79
Other non-current liabilities		
Total non-current liabilities	7,279,288,602.69	5,257,765,860.00
Total liabilities	15,511,222,323.85	13,516,669,553.36
Equity:		
Parent's equity (attributable to the parent)	2,562,898,545.00	2,563,060,895.00
Capital	14,247,927,508.28	14,231,054,756.04
Minority interest	—	1,711,169.00
Other equity	-327,370,661.53	-279,100,142.24
Surplus	1,247,565,522.50	1,247,565,522.50
Unrealized gains	7,215,475,346.06	6,968,417,072.42
Total equity (attributable to the parent)	24,946,496,260.31	24,729,286,934.72
Total equity (attributable to the parent and minority interest)	40,457,718,584.16	38,245,956,488.08

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of Accounting Department:
Chen Zhanyu

Consolidated Income Statement (Continued)

January - September 2019

Items	July - Sept 2019	July - Sept 2018	Jan - Sept 2019	Jan - Sept 2018
I. Operating Income	-9,016,755.16	-122,010,941.32	34,958,479.93	-532,197,468.31
Operating Income				
Operating Income	7,142,372.12	-173,180,224.69	35,946,029.37	-571,964,925.72
() Operating Income	144,152.81	3,756,815.51	-26,694,169.11	-101,521,914.06
1. Cost of Sales	—	—	—	—
2. Selling Expenses	—	—	—	—
3. Administrative Expenses	144,152.81	3,756,815.51	-26,694,169.11	-101,521,914.06
4. Financial Expenses	—	—	—	—
() Operating Income	6,998,219.31	-176,937,040.20	62,640,198.48	-470,443,011.66
1. Selling Expenses	-27,514,726.87	22,492,035.64	-57,540,529.80	29,149,580.97
2. Administrative Expenses	34,512,946.18	-199,429,075.84	120,180,728.28	-499,592,592.63
Operating Income	-16,159,127.28	51,169,283.37	-987,549.44	39,767,457.41
II. Tax Income	626,951,292.40	479,073,767.81	2,490,555,469.23	1,806,839,053.77
Tax Income	554,726,673.16	360,501,362.79	2,099,650,177.36	1,522,187,428.09
Tax Income	72,224,619.24	118,572,405.02	390,905,291.87	284,651,625.68
III. Earnings				
() B	0.22	0.20	0.81	0.83
() D	0.22	0.20	0.81	0.83

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of Accounting Department:
Chen Zhanyu

Income Statement of the Parent Company

January – September 2019

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: CNY; RMB Ten Thousand Yuan

Items	July – Sept 2019	July – Sept 2018	Jan – Sept 2019	Jan – Sept 2018
I. Operating Income	3,815,974.06	—	5,685,313.69	9,433.96
Loss from operations	—	—	—	—
Tax	1,138,885.77	—	2,411,699.94	43,754.06
Share of income from associates	—	—	—	—
Gain from disposal of subsidiaries	65,458,328.69	72,278,881.00	136,505,943.90	151,588,516.01
Royalty	1,400,270.20	—	2,952,245.60	—
Finance	24,847,472.18	29,794,031.27	105,319,187.87	78,043,266.55
Income from investments	143,806,935.92	120,916,769.27	411,681,720.73	331,017,960.01
Other	110,395,009.96	101,566,901.47	300,636,180.35	266,631,390.40
Assets	—	—	—	—
Costs	—	—	—	—
Provision	110,486.49	75,000.00	300,849.09	225,000.00
Income tax	438,727,482.59	409,853,353.52	1,342,948,533.13	1,328,284,941.99
Income from investments	430,736,612.25	389,199,792.25	1,250,403,969.29	1,156,577,651.49
Gain from disposal of subsidiaries	—	—	—	—
Gain from disposal of subsidiaries	-14,794,694.59	66,221,631.43	-36,067,868.78	90,531,856.25
Gain from disposal of subsidiaries	7,349.80	-886.58	7,349.80	-886.58
II. Operating Income ("—" indicates loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Provision	—	—	—	—
Loss	—	—	—	—
III. Total ("—" indicates loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Income	—	—	—	—
IV. Net Income ("—" indicates loss)	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Net Income	335,021,641.51	374,076,186.10	1,065,685,099.62	1,189,374,809.00
Net Income	—	—	—	—



Items	31 December 2018	1 January 2019	Adjustment
Non-current liabilities:			
Long-term debt	8,630,661,547.43	8,630,661,547.43	
Borrowings	4,039,456,986.21	4,039,456,986.21	
Interest payable	—	—	
Provisions	—	—	
Leases	—	325,992,167.00	-325,992,167.00
Long-term debt	416,889,805.19	398,095,841.52	18,793,963.67
Derivatives	363,489,177.57	363,489,177.57	
Derivatives	2,908,359,008.27	2,908,359,008.27	
Other	2,676,545,098.82	2,676,545,098.82	
Trade payables	19,035,401,623.49	19,342,599,826.82	-307,198,203.33
Trade receivables	36,958,648,011.82	37,348,299,890.45	-389,651,878.63
Equity (or shareholders' interests):			
Preferred shares	2,563,060,895.00	2,563,060,895.00	
Common shares	10,544,648,359.54	10,544,648,359.54	
Long-term debt	1,711,169.00	1,711,169.00	
Other	-274,779,732.99	-274,779,732.99	
Share-based payments	2,374,999,312.51	2,374,999,312.51	
Unrealized gains/losses	12,771,518,762.43	12,771,518,762.43	
Trade payables	27,977,736,427.49	27,977,736,427.49	
Net assets	5,614,976,948.17	5,614,976,948.17	
Trade receivables	33,592,713,375.66	33,592,713,375.66	
Trade payables	70,551,361,387.48	70,941,013,266.11	-389,651,878.63

Equity (or shareholders' interests):

For 1 January 2019, the Group's financial statements were audited by MOF.

The Group's financial statements for 2019 were audited by MOF. The Group's financial statements for 2019 were audited by MOF.

Balance Sheet of the Parent Company

Unit: CNY; RMB

Items	31 December 2018	1 January 2019	Adjustment
Current assets:			
Cash	850,102,168.54	850,102,168.54	
Accounts receivable	6,914,735,852.92	6,914,735,852.92	
Interest receivable	230,691,574.83	230,691,574.83	
Dividends receivable	307,409,680.05	307,409,680.05	
Prepaid expenses	1,625,000,000.00	1,625,000,000.00	
Other receivables	158,570,000.00	158,570,000.00	
Total	9,548,408,021.46	9,548,408,021.46	
Non-current assets:			
Long-term investments	5,465,151,645.71	5,465,151,645.71	
Property, plant and equipment	22,999,277,541.00	22,999,277,541.00	
Intangible assets	37,626,487.24	37,626,487.24	
Other non-current assets	184,188,803.45	184,188,803.45	
Financial assets	7,158,298.77	7,158,298.77	
Deferred tax assets	2,305,418.41	2,305,418.41	
Other non-current assets	1,840,272.04	1,840,272.04	
Total	28,697,548,466.62	28,697,548,466.62	
Total	38,245,956,488.08	38,245,956,488.08	
Current liabilities:			
Accounts payable	2,959,000,000.00	2,959,000,000.00	
Prepaid expenses	124,637,901.93	124,637,901.93	
Trade payables	43,694,651.68	43,694,651.68	
Other payables	1,357,247,173.94	1,357,247,173.94	
Interest payable	172,658,261.16	172,658,261.16	
Dividends payable	229,468.00	229,468.00	
Provisions	3,769,010,861.94	3,769,010,861.94	
Other current liabilities	5,313,103.87	5,313,103.87	
Total	8,258,903,693.36	8,258,903,693.36	

Items	31 December 2018	1 January 2019	Adjustment
Non-current liabilities:			
Long-term debt	66,740,000.00	66,740,000.00	
Borrowings	4,039,456,986.21	4,039,456,986.21	
Interest payable	—	—	
Provisions	—	—	
Derivatives	550,000.00	550,000.00	
Deferred tax liabilities	1,151,018,873.79	1,151,018,873.79	
Trade payables	5,257,765,860.00	5,257,765,860.00	
Trade receivables	13,516,669,553.36	13,516,669,553.36	
Equity (including minority interests):			
Preferred shares	2,563,060,895.00	2,563,060,895.00	
Current tax	14,231,054,756.04	14,231,054,756.04	
Long-term equity	1,711,169.00	1,711,169.00	
Other equity	-279,100,142.24	-279,100,142.24	
Share-based payments	1,247,565,522.50	1,247,565,522.50	
Unrealized gains	6,968,417,072.42	6,968,417,072.42	
Trade receivables (including minority interests)	24,729,286,934.72	24,729,286,934.72	
Trade payables (including minority interests)	38,245,956,488.08	38,245,956,488.08	

4.3 Explanation on retrospective adjustments to previous comparative data for the initial implementation of New Financial Instruments Standards and New Lease Standards

For 1 January 2019, the Group has implemented the New Financial Instruments Standards and New Lease Standards.

The Group has implemented the New Financial Instruments Standards and New Lease Standards for the period from 1 January 2019. The Group has not implemented the New Financial Instruments Standards and New Lease Standards for the period from 1 January 2018.

4.4 Audited report

Not applicable.